Abstract: The present invention provides compounds and pharmaceutical compositions of peptidomimetic ligands. The peptidomimetic ligands can be conjugated with phosphonate drugs. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the ?4?1 integrin on mesenchymal stem cells and for the surface of bone.

Abstract: The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the ?4?1 integrin on mesenchymal stem cells and for the surface of bone.

Abstract: Methods of treating osteonecrosis in a subject are provided. In some embodiments, the method comprises administering to a subject having or suspected of having osteonecrosis a pharmaceutical composition comprising a conjugate of an LLP2A peptidomimetic ligand and a bisphosphonate drug. In some embodiments, the pharmaceutical composition comprises a conjugate of LLP2A and alendronate (LLP2A-Ale). In some embodiments, the method further comprises administering exogenous mesenchymal stem cells.

Abstract: The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the ?4?1 integrin on mesenchymal stem cells and for the surface of bone.

Abstract: A chromic luminescent composition and method for fabricating the composition are disclosed. The chromic luminescent composition comprises at least one or more non-luminescent materials and one or more luminescent materials. The one or more non-luminescent materials having absorption spectra that at least partially overlap with the spectrum of incident electromagnetic radiation. The one or more luminescent materials convert at least a portion of energy of incident electromagnetic radiation to a lower energy wavelength. The one or more non-luminescent materials and the one or more luminescent materials are selected such that, when subsequently exposed to incident electromagnetic radiation, color and brightness are substantially modulated through absorption and emission as a function of incident electromagnetic radiation. Also disclosed are a chromic luminescent textile and a method for fabricating the textile.

Abstract: The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the ?4?1 integrin on mesenchymal stem cells and for the surface of bone.

Abstract: Methods of treating osteonecrosis in a subject are provided. In some embodiments, the method comprises administering to a subject having or suspected of having osteonecrosis a pharmaceutical composition comprising a conjugate of an LLP2A peptidomimetic ligand and a bisphosphonate drug. In some embodiments, the pharmaceutical composition comprises a conjugate of LLP2A and alendronate (LLP2A-Ale). In some embodiments, the method further comprises administering exogenous mesenchymal stem cells.

Abstract: The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the ?4?1 integrin on mesenchymal stem cells and for the surface of bone.

Abstract: The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the ?4?1 integrin on mesenchymal stem cells and for the surface of bone.

Abstract: A chromic luminescent composition and method for fabricating the composition are disclosed. The chromic luminescent composition comprises at least one or more non-luminescent materials and one or more luminescent materials. The one or more non-luminescent materials having absorption spectra that at least partially overlap with the spectrum of incident electromagnetic radiation. The one or more luminescent materials convert at least a portion of energy of incident electromagnetic radiation to a lower energy wavelength. The one or more non-luminescent materials and the one or more luminescent materials are selected such that, when subsequently exposed to incident electromagnetic radiation, color and brightness are substantially modulated through absorption and emission as a function of incident electromagnetic radiation. Also disclosed are a chromic luminescent textile and a method for fabricating the textile.

Abstract: A chromic luminescent composition and method for fabricating the composition are disclosed. The chromic luminescent composition comprises at least one or more non-luminescent materials and one or more luminescent materials. The one or more non-luminescent materials having absorption spectra that at least partially overlap with the spectrum of incident electromagnetic radiation. The one or more luminescent materials convert at least a portion of energy of incident electromagnetic radiation to a lower energy wavelength. The one or more non-luminescent materials and the one or more luminescent materials are selected such that, when subsequently exposed to incident electromagnetic radiation, color and brightness are substantially modulated through absorption and emission as a function of incident electromagnetic radiation. Also disclosed are a chromic luminescent textile and a method for fabricating the textile.

Abstract: A chromic luminescent composition and method for fabricating the composition are disclosed. The chromic luminescent composition comprises at least one or more non-luminescent materials and one or more luminescent materials. The one or more non-luminescent materials having absorption spectra that at least partially overlap with the spectrum of incident electromagnetic radiation. The one or more luminescent materials convert at least a portion of energy of incident electromagnetic radiation to a lower energy wavelength. The one or more non-luminescent materials and the one or more luminescent materials are selected such that, when subsequently exposed to incident electromagnetic radiation, color and brightness are substantially modulated through absorption and emission as a function of incident electromagnetic radiation. Also disclosed are a chromic luminescent textile and a method for fabricating the textile.

Abstract: The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the ?4?1 integrin on mesenchymal stem cells and for the surface of bone.

Abstract: The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the ?4?1 integrin on mesenchymal stem cells and for the surface of bone.

Abstract: A chromic luminescent object comprising one or more chromic luminescent compositions incorporated into or onto one or more portions of the object, in which the one or more chromic luminescent compositions are selected such that, when subsequently exposed to incident electromagnetic radiation, at least brightness of the one or more portions of the object is substantially modulated through absorption and emission as a function of incident electromagnetic radiation is disclosed. Also disclosed are methods for fabricating the chromic luminescent object.

Abstract: A chromic luminescent composition and method for fabricating the composition are disclosed. The chromic luminescent composition comprises at least one or more non-luminescent materials and one or more luminescent materials. The one or more non-luminescent materials having absorption spectra that at least partially overlap with the spectrum of incident electromagnetic radiation. The one or more luminescent materials convert at least a portion of energy of incident electromagnetic radiation to a lower energy wavelength. The one or more non-luminescent materials and the one or more luminescent materials are selected such that, when subsequently exposed to incident electromagnetic radiation, color and brightness are substantially modulated through absorption and emission as a function of incident electromagnetic radiation. Also disclosed are a chromic luminescent textile and a method for fabricating the textile.

Abstract: The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the ?4?1 integrin on mesenchymal stem cells and for the surface of bone.

Abstract: A chromic luminescent object comprising one or more chromic luminescent compositions incorporated into or onto one or more portions of the object, in which the one or more chromic luminescent compositions are selected such that, when subsequently exposed to incident electromagnetic radiation, at least brightness of the one or more portions of the object is substantially modulated through absorption and emission as a function of incident electromagnetic radiation is disclosed. Also disclosed are methods for fabricating the chromic luminescent object.

Abstract: A chromic luminescent composition and method for fabricating the composition are disclosed. The chromic luminescent composition comprises at least one or more non-luminescent materials and one or more luminescent materials. The one or more non-luminescent materials having absorption spectra that at least partially overlap with the spectrum of incident electromagnetic radiation. The one or more luminescent materials convert at least a portion of energy of incident electromagnetic radiation to a lower energy wavelength. The one or more non-luminescent materials and the one or more luminescent materials are selected such that, when subsequently exposed to incident electromagnetic radiation, color and brightness are substantially modulated through absorption and emission as a function of incident electromagnetic radiation. Also disclosed are a chromic luminescent textile and a method for fabricating the textile.